Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Peter MacCallum Cancer Centre, East Melbourne, Australia



Survival: 13.6 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: Australia
   
City/State/Province: East Melbourne
   
Hospital: Peter MacCallum Cancer Centre
   
Journal: Link
   
Date: 2/2014

Description:
Patients:
This phase 3 study involved metastatic melanoma patients with a mutation in the BRAF gene who had not received prior treatment. Patients were divided into two treatment groups. Group A consisted of 337 patients with a median age of 56 years, 59% of whom were male. Group B had 338 patients with a median age of 52.5 years, 54% of whom were male.

Treatment:
Patients in group A were treated with vemurafenib, a biologic therapy agent that is an inhibitor of the BRAF protein.

Patients in group B received chemotherapy with dacarbazine.

Toxicities:
There were eight unspecified grade 5 adverse events reported for group A. Grade 4 neutropenia and liver toxicity were also reported.

There were seven unspecified grade 5 adverse events reported for group B. Grade 4 neutropenia was also reported.

Results:
The median overall survival rates for groups A and B were 13.6 and 9.7 months, respectively.

Support:
This study was supported by Hoffmann-La Roche-Genentech, a pharmaceutical company.

Correspondence: Dr. Grant A McArthur; email: grant.mcarthur@petermac.org

E-mail to a Friend Email Physician More Information